Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China

• Main Authors: Wang Cao (Author), Yuncui Yu (Author), Yingpeng Qiu (Author), Lu Liu (Author), Hao Zhang (Author), Liwei Shi (Author), Yue Xiao (Author), Lulu Jia (Author), Ruidong Zhang (Author), Xiaoling Wang (Author)
• Format: Book
• Published: BMC, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Dasatinib and imatinib are the recommended tyrosine kinase inhibitors (TKIs) for treating pediatric Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL), and the one which has been approved indication in China is imatinib. Recently, clinical demand for Ph + ALL treatment...